Citation Impact
Citing Papers
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
2023 Standout
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
2018
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Non-traditional Antibacterial Therapeutic Options and Challenges
2019
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
2018
De novoisolation of antibodies with pH-dependent binding properties
2015
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
2011
COVID-19: A promising cure for the global panic
2020 Standout
Antibiotic development — economic, regulatory and societal challenges
2019 Standout
The Role of Macrophages in Staphylococcus aureus Infection
2021
Skeletal infections: microbial pathogenesis, immunity and clinical management
2022 Standout
Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
2018
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Targeting FcRn to Generate Antibody-Based Therapeutics
2018
Iron regulation by hepcidin
2013
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
2013
Harnessing innate immunity in cancer therapy
2019 Nature
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
2019
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
2021 StandoutNobel
Anemia of Chronic Disease
2005 Standout
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
Monoclonal antibody-based therapies for bacterial infections
2019
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
2016
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
2010
Bacterial Antibiotic Resistance: The Most Critical Pathogens
2021 Standout
Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms
2019
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Works of Yuling Wu being referenced
Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults
2018
Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys
2010
Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins
2008
Characterisation of anti‐alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin
2018
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
2016
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
2018
Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations
2017
Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors
2017